Katie Kalvaitis , 2025-05-13 17:31:00
The Advance-HTN trial compared treatment with the aldosterone synthase inhibitor lorundrostat vs. placebo for blood pressure reduction among adults with treatment-resistant hypertension.
Read Healio’s in-depth coverage of the Advance-HTN trial, including expert perspective.
The randomized, double-blind, placebo-controlled trial enrolled 285 patients with treatment-resistant hypertension, which was defined as an automatic systolic BP of 140 to 180 mm Hg while taking two to five BP medications.
At 12 weeks, mean decrease in 24-hour average systolic BP was 15.4 mm Hg for patients assigned 50 mg lorundrostat (Mineralys Therapeutics), 13.9 mm Hg for patients who escalated from 50 to 100 mg and 7.4 mm Hg for those assigned placebo.
Researchers reported a higher incidence of hyperkalemia in the two lorundrostat groups.
The Advance-HTN trial was presented at the American College of Cardiology Scientific Session and published in The New England Journal of Medicine.
Read Healio’s complete coverage of ACC 2025 here.
